摘要
[摘要 ] 目的 探讨进展期胰腺癌患者实施厄洛替尼联合化疗治疗的临床效果。方法 方便选择 100例进展期胰腺癌患者，时间： 2018年 2月— 2020年 2月，随机电脑排序分为两组：对照组、研究组，其中，对照组予以口服厄洛替尼单一治疗，研究组予以厄洛替尼联合化疗治疗。对组间的不良反应发生率（胃肠道反应率、皮疹率、乏力率）与治疗总有效率进行指标对比。结果 研究组不良反应发生率（胃肠道反应率： 10.00%、皮疹率： 4.00%、乏力率： 6.00%）比对照组（胃肠道反应率： 20.00%、皮疹率： 12.00%、乏力率： 8.00%）低，且其治疗总有效率（ 60.00%）指标比对照组（ 40.00%）更高，差异有统计学意义（ χ2=4.76、 4.00， P<0.05）。 结论 厄洛替尼联合化疗治疗进展期胰腺癌的临床效果显著，可以有效改善患者的临床症状，降低其不良反应发生率和提高临床治疗效果。
[关键词 ] 厄洛替尼 ;化疗 ;进展期胰腺癌 ;临床效果
[Abstract] Objective To investigate the clinical effect of erlotinib combined with chemotherapy in patients with advanced pancreatic cancer. Methods convenient selection of 100 cases of advanced pancreatic cancer patients, time: February 2018 to February 2020, randomly divided into two groups: the control group and the study group, the control group was given oral erlotinib single treatment, the study group was given erlotinib combined with chemotherapy. The incidence of adverse reactions (gastrointestinal reaction rate, rash rate, fatigue rate) and the total effective rate were compared between the two groups. Results the incidence of adverse reactions in the study group (gastrointestinal reaction rate: 10.00%, rash rate: 4.00%, fatigue rate: 6.00%) was lower than that of the control group (gastrointestinal reaction rate: 20.00%, rash rate: 12.00%, fatigue rate: 8.00%), and the total effective rate (60.00%) of the study group was higher than that of the control group (40.00%), the difference was statistically significant (χ 2 = 4.76, 4.00, P < 0.05). Conclusion erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer has significant clinical effect, which can effectively improve the clinical symptoms of patients, reduce the incidence of adverse reactions and improve the clinical treatment effect.
出版日期
2020年10月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
